

Charity number: 1166985

**THE LIVER GROUP CHARITY CIO**  
**UNAUDITED ANNUAL REPORT AND**  
**ACCOUNTS**  
**YEAR ENDED 31 DECEMBER 2017**



**LUBBOCK FINE**  
**Chartered Accountants**  
**Paternoster House**  
**65 St Paul's Churchyard**  
**London EC4M 8A**

# THE LIVER GROUP CHARITY CIO

## CONTENTS

---

	Page
<b>Reference and Administrative Details of the Charity, its Trustees and Advisers</b>	1
<b>Trustees' Report</b>	2 - 5
<b>Chairman's Statement</b>	6
<b>Independent Examiner's Report</b>	7 - 8
<b>Statement of Financial Activities</b>	9
<b>Balance Sheet</b>	10
<b>Notes to the Financial Statements</b>	11 - 17
The following pages do not form part of the statutory financial statements:	
<b>Donations to the "Liver for Life" appeal</b>	18 - 19
<b>Scientific publications and presentations</b>	20 - 21

**THE LIVER GROUP CHARITY CIO**

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 DECEMBER 2017**

---

**Trustees**

Sarah Bates  
Susan Eggleton  
Dr Martin Giles  
Kay Glendinning MBE  
Dr David Holbrook ( Chairman)  
Professor Clare Selden

**Charity registered  
number**

1166985

**Principal office**

C/O Institute for Liver and Digestive Health  
Royal Free Hospital Campus - University College Medical School  
Rowland Hill Street  
Hampstead  
NW3 2PF

**Patron**

Prof Sir Roger Penrose OM FRS

**Accountants**

Lubbock Fine  
Chartered Accountants & Statutory Auditors  
Paternoster House  
65 St Paul's Churchyard  
London  
EC4M 8AB

## **THE LIVER GROUP CHARITY CIO**

### **TRUSTEES' REPORT**

#### **FOR THE YEAR ENDED 31 DECEMBER 2017**

---

The Trustees present the annual report together with the financial statements of The Liver Group Charity CIO for the period from 1 January 2017 to 31 December 2017. The Trustees confirm that the Annual Report and financial statements of the Charity comply with the current statutory requirements, the requirements of the Charity's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) as amended by Update Bulletin 1 (effective 1 January 2015).

#### **REFERENCE AND ADMINISTRATIVE DETAILS**

The Liver Group Charity CIO ("the Charity") is registered with the Charity Commission of England and Wales, under registration number 1166985.

The Charity was registered on 6 May 2016 as a Charitable Incorporated Organisation, and as at 30 September 2016 took over the activities and assets of The Liver Group (registered charity number 1024533) which has subsequently been closed.

The principal operating address is c/o UCL Institute of Liver and Digestive Health, UCL - Royal Free Hospital Campus, University College Medical School, Upper Third Floor, Rowland Hill St, Hampstead, London NW3 2PF.

The financial statements cover the 12 months from the 1 January 2017 to 31 December 2017. The prior period financial statements cover the period from 6 May 2016 to 31 December 2016, therefore the comparative results are not entirely comparable.

The Trustees who served or who have been appointed since the end of the period were:

Mrs Sarah Bates  
Ms Susan Eggleton  
Dr Martin Giles (appointed 12th June 2018)  
Mrs Kay Glendinning  
Professor Humphrey Hodgson (Chairman, resigned 7th February 2018)  
Dr David Holbrook (Chairman)  
Professor Clare Selden

Prof Sir Roger Penrose OM FRS — Patron

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

The Board of Trustees is collectively responsible for the competent management of the organisation in accordance with its objectives which are set out in the Trust Deed which is the Charity's governing document. The Board meets twice a year to monitor the organisation's strategy and activities. The members are able to draw on relevant board experience in board deliberations.

The Charity does not have any employees and its day to day activities are carried out by researchers from University College London under the supervision of two Trustees. The Trustees have agreed a position that should any profits arise from the intellectual property in the research being carried out by the team generally, and in conjunction with the various other parties involved in that work, the Charity would be entitled to a proportion of such amounts as per the Association of Medical Research Documentation (AMRC).

If the need arose to appoint a new trustee the remaining Trustees would identify and appoint an appropriate person. During 2017, the requirement to increase the number of Trustees was identified and Martin Giles was appointed in June 2018.

The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees' responsibilities, the governing documents, administrative procedures and the history and philosophical approach of the Charity.

## **THE LIVER GROUP CHARITY CIO**

### **TRUSTEES' REPORT (continued)**

#### **FOR THE YEAR ENDED 31 DECEMBER 2017**

---

The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation.

#### **OBJECTIVES AND ACTIVITIES**

The objects of the charity are:

- The relief of patients suffering from disease of the liver and genetic defects affecting the liver.
- The promotion of research into the causes and treatment of diseases of the liver on terms that the results of such research are published.
- Without prejudice to the generality of the foregoing to fund and support existing and future research into such matters at UCL Medical School (Liver Group) at the Royal Free Hospital or any other establishment into which such unit may be amalgamated and transferred in the future.

The principal activity of the Charity currently is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing "Liver for Life" Appeal.

All the activities of the Charity were undertaken to further its purposes for the public benefit in line with the Charity's long-term objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 17 of the Charities Act 2011 having due regard of the public benefit guidance published by the Commission.

#### **ACHIEVEMENTS AND PERFORMANCE**

##### **FINANCIAL REVIEW**

The organisation remains funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations. During the year external donations totalled £69,401 (2016: £50,336)

The majority of funds are spent on paying the cost of researchers, as well as the required consumables and equipment for the research to continue. As evidenced by the publications, the Charity's current aim to develop a bio-artificial liver machine has moved forward from the medium scale to human scale.

The following period will see a move towards clinical use for this machine. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure. For 2017, expenditure totalled £75,089 (2016: £22,593).

Except for such funds as the Trustees consider prudent to maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the "Liver for Life" Appeal and the general charitable objects of the Charity. The Trustees consider that £70,000 of unrestricted reserves is more than sufficient to fund 12 months of current operations.

As at 31 December 2017 the unrestricted fund had a committed surplus of £479,761 (2016: £467,467) and the restricted fund had a surplus of £50,000 (2016: £65,963). As disclosed in note 13, some of the Charity's unrestricted fund is already committed to existing research and PhD students, and their necessary consumables.

As the bio-artificial liver project nears clinical scale and development for clinical trial, the costs are rapidly increasing necessitating considerable further fund-raising.

## THE LIVER GROUP CHARITY CIO

### TRUSTEES' REPORT (continued)

FOR THE YEAR ENDED 31 DECEMBER 2017

---

#### FACTORS RELEVANT TO ACHIEVE OBJECTIVES

- Research output, intellectual property gained and achievement of milestones towards moving the bioartificial liver project from the bench to the bedside. Further details are set out in the Chairman's report on page 6.
- Administrative charitable activities are limited to fundraising for the research endeavour. This is achieved by written applications to known grant giving organisations, small and large companies via the CEOs or other appropriate individual or wealthy individual donors. The Charity also has a web-page with an opportunity to donate via Charities Aid Foundation and other platforms.
- Indicators of achievements are success in the research aims and, in addition, the total funds raised in a particular year. These rarely exceed our expenditure for the year.
- The Charity is one of many sourcing the same research funding; given the difficult position most UK universities find themselves in, there is increasing competition for funds. Until government resources fill the gap between the costs and current funding of medical research the Charity's efforts will become more difficult each year. Notwithstanding this difficult climate, the Charity continues to explore every avenue to increase funding from grants and donations.
- The charity signed an agreement with Asanka Da Silva, regarding his new product, a health drink, LIVON in which a small percentage of its sales would be donated to the Liver Group Charity.
- It is noteworthy that in January 2018 the UCL research group working on the bioartificial liver machine (BAL) were awarded grant funding (£1.6m) from National Institutes for Health Research, an i4i product development award, to produce the patient facing parts of the BAL as disposables, as is required by the regulatory Authorities for items for human use. This funding is not to the Charity but to the UCL research group itself.

#### GOING CONCERN

After making appropriate enquiries, the trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

#### PLANS FOR FUTURE PERIODS

The Charity aims to continue its medical research goals, at a pace commensurate with funding opportunities. With appropriate funding, it sees the bio-artificial liver machine project reaching the clinical trial assessment within four years.

The Charity will continue fundraising via requests to other Grant making trusts, public appeals, private requests, sponsored events and other means as the mainstay of our strategy to ensure the Charity remains a going concern.

#### TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

**THE LIVER GROUP CHARITY CIO**

**TRUSTEES' REPORT (continued)**

**FOR THE YEAR ENDED 31 DECEMBER 2017**

---

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report was approved by the Trustees, on \_\_\_\_\_ and signed on their behalf by:

**David Holbrook**  
Chairman

## THE LIVER GROUP CHARITY CIO

### CHAIRMAN'S STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2017

---

The chairman presents his statement for the period.

The results of the large experimental trial of our bioartificial liver were published this year, placing in the public domain proof of its efficacy when applied in a large animal. This study, coordinated and performed between UCL and the University of Cape Town, represented a huge scientific effort, preparing the alginate-encapsulated cells that constitute the active biological component of the device in London, and air-freighting them to the other side of the world where the experiments were performed. In retrospect, the logistic challenges involved in this, ensuring maintenance of cell function during transport, proved helpful information on various issues that we have now solved, relevant to the use of our machine in clinical practice.

The trial results, which demonstrate some extraordinary improvements in the manifestations of liver failure, are of course being utilised for the unlocking of the further funding needed to get to the stage of our first-in-man clinical trial. As Humphrey outlined last year, this funding must be sought in packets from different sources, separately covering design and production of the clinical-ready device, and the processes of cryopreservation, and a new approach to enhancing treating the sepsis that often complicates liver failure. Although we raise money from grant-giving bodies for these work packages, the support to the charity from our donors becomes perhaps even more important, as we often need to tide-over between grant income, and as always we are hugely grateful to all our supporters for their contributions.

The Charity's success of course is dependent on the scientists who work on the project, and it is a pleasure to acknowledge them, and of course our trustee Prof Clare Selden who drives the laboratory work. Again, we had the help of two intercalating students, Catriona Williams and Maria Khaliq, from the University of Bath in the administration of the Charity, whilst they also gained some practical scientific experience.

Finally, during this year we completed all the formalities associated with having changed our status, in 2016, ceasing to be 'The Liver Group' and becoming 'The Liver Group Charity', a 'CIO' - Charitable Incorporated Organisation - following the Charities Commission's guidance. Our charity identification number changed as a result, now 1166985 (was 1024533). We are particularly grateful to one of our trustees, Sarah Bates, who helped facilitate the process.

Humphrey Hodgson  
Chairman: 1993 - 7th February 2018

Name David Holbrook  
Current Chairman

Date



## **THE LIVER GROUP CHARITY CIO**

### **INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2017**

---

#### **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE LIVER GROUP CHARITY CIO (the 'Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the Year ended 31 December 2017.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

#### **RESPONSIBILITIES AND BASIS OF REPORT**

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

The charity's trustees consider that an audit is not required for this year under section 144 of the 2011 Act and that an independent examination is needed.

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act, and stated whether particular matters have come to my attention.

#### **INDEPENDENT EXAMINER'S STATEMENT**

My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

**THE LIVER GROUP CHARITY CIO**

**INDEPENDENT EXAMINER'S REPORT (continued)  
FOR THE YEAR ENDED 31 DECEMBER 2017**

---

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed:

Dated:

Lee Facey

**LUBBOCK FINE**

Chartered Accountants & Statutory Auditors

Paternoster House  
65 St Paul's Churchyard  
London  
EC4M 8AB

THE LIVER GROUP CHARITY CIO

STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2017

	Note	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
<b>INCOME FROM:</b>					
Donations and legacies	2	69,401	-	69,401	555,561
Investments	3	2,019	-	2,019	462
<b>TOTAL INCOME</b>		<u>71,420</u>	<u>-</u>	<u>71,420</u>	<u>556,023</u>
<b>EXPENDITURE ON:</b>					
Charitable activities	5-8	59,126	15,963	75,089	22,593
<b>TOTAL EXPENDITURE</b>		<u>59,126</u>	<u>15,963</u>	<u>75,089</u>	<u>22,593</u>
<b>NET BEFORE OTHER RECOGNISED GAINS AND LOSSES</b>		12,294	(15,963)	(3,669)	533,430
<b>NET MOVEMENT IN FUNDS</b>		12,294	(15,963)	(3,669)	533,430
<b>RECONCILIATION OF FUNDS:</b>					
Total funds brought forward		467,467	65,963	533,430	-
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><u>479,761</u></u>	<u><u>50,000</u></u>	<u><u>529,761</u></u>	<u><u>533,430</u></u>

The notes on pages 11 to 17 form part of these financial statements.

THE LIVER GROUP CHARITY CIO

BALANCE SHEET  
AS AT 31 DECEMBER 2017

	Note	£	2017 £	£	2016 £
<b>CURRENT ASSETS</b>					
Debtors	9	-		383	
Cash at bank and in hand		577,090		572,306	
		<u>577,090</u>		<u>572,689</u>	
<b>CREDITORS:</b> amounts falling due within one year	10	(47,329)		(39,259)	
<b>NET CURRENT ASSETS</b>			<u>529,761</u>		<u>533,430</u>
<b>NET ASSETS</b>			<u>529,761</u>		<u>533,430</u>
<b>CHARITY FUNDS</b>					
Restricted funds	11		50,000		65,963
Unrestricted funds	11		479,761		467,467
<b>TOTAL FUNDS</b>			<u>529,761</u>		<u>533,430</u>

The financial statements were approved by the Trustees on

and signed on their behalf, by:

**David Holbrook**

The notes on pages 11 to 17 form part of these financial statements.

**THE LIVER GROUP CHARITY CIO**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**

---

**1. ACCOUNTING POLICIES**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011.

The Liver Group Charity CIO constitutes a public benefit entity as defined by FRS 102.

The comparative figures are for the period from 6 May 2016 to 31 December 2016.

**1.2 Going Concern**

The charity is mainly reliant upon donations to raise revenue to meet future expenditure. The Trustees consider that it is appropriate to prepare the financial statements on a going concern basis. This assumes that the charity will be successful in its fundraising activities. The financial statements do not include any adjustments that would result if insufficient funds are raised.

**1.3 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**1.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Charitable activity costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity.

**1.5 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**THE LIVER GROUP CHARITY CIO**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**

---

**1. ACCOUNTING POLICIES (continued)**

**1.6 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.7 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.8 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

Trade and other creditors are recognised at the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid.

**1.9 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.10 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.11 Donated goods and services**

The Charity does not value donated services in the accounts. Services that are received, such as volunteers' time and the use of the laboratory space at University College London are either deemed to not be material or too onerous to value for a charity of this size.

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2017

2. INCOME FROM DONATIONS AND LEGACIES

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Donations	69,401	-	69,401	50,336
Transfer from The Liver Group on 30 September 2016	-	-	-	505,225
	<u>69,401</u>	<u>-</u>	<u>69,401</u>	<u>555,561</u>
Total donations and legacies	<u>69,401</u>	<u>-</u>	<u>69,401</u>	<u>555,561</u>
<b>Total 2016</b>	<u><u>469,121</u></u>	<u><u>86,440</u></u>	<u><u>555,561</u></u>	

3. INVESTMENT INCOME

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Bank Interest	2,019	-	2,019	462
	<u>2,019</u>	<u>-</u>	<u>2,019</u>	<u>462</u>
<b>Total 2016</b>	<u><u>462</u></u>	<u><u>-</u></u>	<u><u>462</u></u>	

4. ANALYSIS OF EXPENDITURE BY ACTIVITIES

	Activities undertaken directly 2017 £	Support costs 2017 £	Total 2017 £	Total 2016 £
Charitable costs	71,567	3,522	75,089	22,593
	<u>71,567</u>	<u>3,522</u>	<u>75,089</u>	<u>22,593</u>
<b>Total 2016</b>	<u><u>21,079</u></u>	<u><u>1,514</u></u>	<u><u>22,593</u></u>	

5. ANALYSIS OF EXPENDITURE ON CHARITABLE ACTIVITIES

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £	Total funds 2016 £
Charitable costs	59,126	15,963	75,089	22,593
	<u>59,126</u>	<u>15,963</u>	<u>75,089</u>	<u>22,593</u>
<b>Total 2016</b>	<u><u>2,116</u></u>	<u><u>20,477</u></u>	<u><u>22,593</u></u>	

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2017

6. DIRECT COSTS

	Activities £	Total 2017 £	Total 2016 £
Research consumables and laboratory	-	-	602
Researchers (employed by UCL)	71,567	71,567	20,477
	<u>71,567</u>	<u>71,567</u>	<u>21,079</u>
<b>Total 2016</b>	<u>21,079</u>	<u>21,079</u>	

7. SUPPORT COSTS

	Activities £	Total 2017 £	Total 2016 £
Travel	1,378	1,378	750
Accountancy fee	1,050	1,050	764
Sundry expenses	164	164	-
Independent examination fees (governance)	750	750	-
Bank charges	180	180	-
	<u>3,522</u>	<u>3,522</u>	<u>1,514</u>
<b>Total 2016</b>	<u>1,514</u>	<u>1,514</u>	

8. STAFF COSTS

The Charity did not have any employees during the period but it did use researchers who are themselves employed by University College London.

The average weekly number of employees of UCL seconded to The Liver Group Charity CIO during the period was one. At the period-end there was one employee of UCL working on The Liver Group Charity CIO research. In addition, there were two PhD students paid a stipend and fees via UCL.

During the period, a number of volunteers gave their time to assist the Charity. No remunerations, other than travel expense to and from the place of work, were paid to them and the Charity thanks them for their generosity.

The Charity has no employees other than the Trustees, who did not receive any remuneration (2016 - £NIL).



THE LIVER GROUP CHARITY CIO  
 NOTES TO THE FINANCIAL STATEMENTS  
 FOR THE YEAR ENDED 31 DECEMBER 2017

9. DEBTORS

	2017 £	2016 £
Prepayments and accrued income	-	383

10. CREDITORS: Amounts falling due within one year

	2017 £	2016 £
Amounts due to UCL	13,620	15,121
Other creditors	18,511	-
Accruals and deferred income	15,198	24,138
	<u>47,329</u>	<u>39,259</u>

11. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

	Balance at 1 January 2017 £	Income £	Expenditure £	Balance at 31 December 2017 £
<b>General funds</b>				
General Funds	467,467	71,420	(59,126)	479,761
<b>Restricted funds</b>				
The Garfield Weston Foundation	50,000	-	-	50,000
Peter Stebbings Memorial Charity	15,963	-	(15,963)	-
	<u>65,963</u>	<u>-</u>	<u>(15,963)</u>	<u>50,000</u>
Total of funds	<u>533,430</u>	<u>71,420</u>	<u>(75,089)</u>	<u>529,761</u>

Restricted funds have arisen from donations received by the Charity from the donors detailed above.

The Garfield Weston Foundation – Was received for key equipment required to enable cryopreservation of biomass for a bioartificial liver machine developed to treat patients with severe acute liver failure. The fund is applied in accordance with the restrictions imposed.

Peter Stebbings Memorial Charity – Was transferred from the Liver Group to the Liver Group Charity CIO. It has been received towards the employment of postdoctoral researchers to develop a liver support device to treat patients with liver illnesses. The fund is applied in accordance with the restrictions imposed.

THE LIVER GROUP CHARITY CIO  
 NOTES TO THE FINANCIAL STATEMENTS  
 FOR THE YEAR ENDED 31 DECEMBER 2017

11. STATEMENT OF FUNDS (continued)

STATEMENT OF FUNDS - PRIOR YEAR

	Balance at 6 May 2016 £	Income £	Expenditure £	Balance at 31 December 2016 £
<b>General funds</b>				
General Funds	-	469,583	(2,116)	467,467
<b>Restricted funds</b>				
The Garfield Weston Foundation	-	50,000	-	50,000
Peter Stebbings Memorial Charity	36,440	-	(20,477)	15,963
	36,440	50,000	(20,477)	65,963
Total of funds	36,440	519,583	(22,593)	533,430

12. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR

	Unrestricted funds 2017 £	Restricted funds 2017 £	Total funds 2017 £
Current assets	527,090	50,000	577,090
Creditors due within one year	(47,329)	-	(47,329)
	479,761	50,000	529,761

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR

	Unrestricted funds 2016 £	Restricted funds 2016 £	Total funds 2016 £
Current assets	506,726	65,963	572,689
Creditors due within one year	(39,259)	-	(39,259)
	467,467	65,963	533,430

**THE LIVER GROUP CHARITY CIO**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**

---

**13. GRANT COMMITMENTS**

	<b>Total 2017 £</b>	<b>Total 2016 £</b>
At 31 December 2017 the Charity had commitments as follows:		
Within one year	<u>18,511</u>	<u>-</u>

As at 31 December 2017, the Charity had committed to pay the fees of a post doctorate student totalling £55,534. However, an alternative source of funding was found for this student post year end, therefore the Charity only had to pay his costs up until the 1 May 2018, which totalled approximately £18,511. This amount has been recognised for in full in the accounts for the year ended 31 December 2017.

The Charity has outstanding commitments at 31 December 2017, to pay the fees and stipend costs of two PHD students. The trustees estimate these commitments to total £76,000, which they will only be committed to pay if UCL find no alternative source of funding for them. In the current year UCL found alternative funding for 100% of these costs, and therefore there has been no expense recognised in respect of this commitment. The Charity has also committed to pay the consumable costs of these students however due to the nature of these, costs will vary yearly and therefore there is no accurate estimation of the costs that will be incurred. Due to the uncertainty of the actual amount that will need to be paid by the Charity in relation to these commitments, no provision has been made in the accounts.

**14. RELATED PARTY TRANSACTIONS**

There were no related party transactions identified during the period.

## THE LIVER GROUP CHARITY CIO

### DONATIONS TO THE "LIVER FOR LIFE" APPEAL

---

We are grateful to the following for donations to the "Liver for Life" Appeal

A Davies (In memory of Jilly Davies)	Everyman Cinemas	Maureen Ng (In memory of Sai Peng)
A Dowse	Fishmonger's Company	Menzies Group
A Gregory	Friends Provident	MF Cullen (In memory of Jilly Davies)
A Silva		Morgan Advanced Materials
Amanda Ebanks	G Davies	
Armourers & Brasiers Gauntlet Trust	Gary Ingham Hair Salon and Spa	N Low
Associated British Ports Ltd	Gauchos	N Smith Charitable Settlement
	Generosity (by IndieGogo)	New Brunswick
BAE Systems		P Davies (In memory of Dr C Davies)
Bank of England		Pamela Godfrey
Barclays Bank (Knightsbridge Limited)	Glaxo Plc	P Smith
Billingsgate Christian Mission Charitable Trust	Guardian Royal Exchange Plc	Peter Stebbings Memorial Charity
BTR PLC	Haymills Charitable Trust	Pfizer Ltd
	HJ Heinz Co Ltd Charitable Trust	PWC
	HMRC	
C Binks		R C & Mrs D Ward
C Collins		R F Venn (In memory of Jilly Davies)
C Jones (In memory of Jilly Davies)	Hon C A Pearson's Charity Trust	R Stowell
C W Mills	Honeywell	Rio Tinto Plc
CAF		
CE Heath PLC	J Davies (In memory of Jilly Davies)	
Chapman Charitable Trust	J Gibbs	Robert Fleming Holidays Ltd
Charities Trust	Jardine Insurance Services Ltd	Robert Luff Foundation Ltd
Citibank	JM Elgie (In memory of Jilly Davies)	Rowan Bentall Charitable Trust
Communis Plc	John Taylor Funeral Service	Royal London Insurance Ltd / Scottish Life
Conoco Philips	Just Text Giving	Rudolf Wolf & Co
Cookson Group Plc		
Courage Brewery	KPMG Pet Marwick	Sandoz
Coutts Charitable Trust		S Collins
CSB Nitsch	Laings of London	Schroders Plc
C Selden	Land Securities Plc	Seagrams Distillery Charitable Trust
	Life Technologies	Securicor Plc
D Davies (In memory of Jilly Davies)	L Joyce	S Guglani
Dako Limited	Lloyds Bank Plc	
Daunt Book	Lords Hampstead	
E Wright	Mackintosh Foundation	Sir Samuel Scott of Yews Trust
EJH Stephenson (Deceased) Charitable Trust	Mars UK Corporate Services Ltd	Smiths Group PLC
Everyclick & GAYL	M Cooper	Snappy Snaps
	M Matthews	Societe Generale UK

## THE LIVER GROUP CHARITY CIO

### DONATIONS TO THE "LIVER FOR LIFE" APPEAL

---

Sunlife Assurance	The SMB Trust
	The Sobell Foundation
The Arnold Burton 1998 Charitable Trust	The Steel Charitable Trust
The Astor Foundation	The Walter Guinness Charitable Trust
The Balint Family Trust	The Worshipful Company of Saddlers
The Bergqvist Charitable Trust	The Worshipful Company of Salters
The Bernard Sunley Charitable Foundation	Thomson Corporation Charitable Trust
The Big Give	Thriplow Charitable Trust
The Boots Charitable Trust	TI Group
The Bowerman Memorial Trust	Tom and Sheila Springer Charity
The Catherine Cookson Charitable Trust	Tomkins Plc
The Chandris Foundation	
The Charles Littlewood Hill Charitable Trust	Vauxhall
The Childwick Trust	Violet M Richards Charity
The Clothworkers Foundation	
The Cooper Charitable Trust	Wagamamas
The Dunhill Medical Trust	Waterstones
The Economist	Whitbread Plc
The Eranda Foundation	Wilkinson Hardware Stores Ltd
The Fitton Trust	William & Mabel Morris Charitable Trust
The Forte Charitable Trust	
The Garfield Weston Foundation	Yorkshire and Clydesdale Bank
The Gerald Palmer Eling Trust	
The Haberdashers Company	
The Hamamelis Trust	Zara Restaurant
The Hartnett Charitable Trust	
The Hospital Saturday Fund	We would also like to thanks those who have donated anonymously.
The John & Celia Bonham Christie Charitable Trust	
The John Ellerman Foundation	
The Lennox Hannay Charitable Trust	
The Loke Wan Tho Foundation	
The Mary Webb Trust	
The Michael and Anna Wix Charitable Trust	
The Peter Bowring Charitable Trust	
The Pharmaceutical Brand Consultancy	
The Really Helpful Group	
The Reuben Foundation	
The Roger Vere Foundation	

## THE LIVER GROUP CHARITY CIO

### PUBLICATIONS ARISING FROM THE WORK OF THE LIVER GROUP CHARITY IN 2017

---

#### **Impact of Storage at -80°C on Encapsulated Liver Spheroids After Liquid Nitrogen Storage.**

Kilbride P, Gonzalez-Molina J, Maurmann N, Mendonça da Silva J, Gibbons S, Selden C, Fuller B, Morris J. *Biores Open Access*. Jun 2016. 5(1):146-54.

#### **Liquidus Tracking: Large scale preservation of encapsulated 3-D cell cultures using a vitrification machine.**

Puschmann E, Selden C, Butler S, Fuller B. *Cryobiology*. 2017 Jun. 76: 65-73.

#### **Cryopreservation and re-culture of a 2.3 litre biomass for use in a bioartificial liver device.**

Kilbride P, Lamb S, Gibbons S, Bundy J, Erro E, Selden C, Fuller B, Morris J. *PLOS ONE*. Aug 2017. 12(8).

#### **A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure.**

Selden C, Bundy J, Erro E, Puschmann E, Miller M, Kahn D, Hodgson H, Fuller B, Gonzalez-Molina J, Le Lay A, Gibbons S, Chalmers S, Modi S, Thomas A, Kilbride P, Isaacs A, Ginsburg R, Ilesley H, Thomson D, Chinnery G, Mankahla N, Loo L, Spearman CW. *Sci Rep*. Nov 2017. 7(1), 14518.

#### **Presentations at national and international scientific meetings during 2017**

##### **Leukocyte response to an alginate-encapsulated liver-derived cell line used in a bioartificial liver device.**

Gonzalez-Molina J., Erro E., Wright G., Bundy J., Chalmers S.A., Fuller B., Selden C.

Presented at UCL IIT Immunology Symposium with Pears Lecture.

Royal Free Hospital, London, UK.

13<sup>th</sup> June 2017.

##### **BioArtificial Liver Machine to Treat Patients With Acute Liver Failure: GMP Methodology For Clinical Application and Results in a Pre-Clinical Trial.**

Erro E, Bundy J, Modi S, Chalmers S, Fuller B, Hodgson H, Kahn D, Thomson D, Chinnery G, Miller M, Mankahla N, Isaacs A, Lucas R, Botes I, Dankers G, Ilesley H, Loo L, Ginsburg R, Spearman W, Selden C.

Presented at UCL IIT Immunology Symposium with Pears Lecture.

Royal Free Hospital, London, UK.

13<sup>th</sup> June 2017.

##### **Extracellular viscosity enhances mesenchymal migration and alignment in liver cancer cells.**

Gonzalez-Molina J., Borghesan M., Fuller B., Selden C.

Presented at EMBO/EMBL Symposium: Mechanical forces in biology.

EMBL Heidelberg, Germany.

12 – 15<sup>th</sup> Jul 2017.

##### **Effect of Warming Rate On Post-Thaw Recovery Of Cryopreserved Alginate Encapsulated Liver Spheroids.**

Awan M, Mendonca-Silva J, Erro E, Gurruchaga H, Fuller B and Selden C.

## THE LIVER GROUP CHARITY CIO

### PUBLICATIONS ARISING FROM THE WORK OF THE LIVER GROUP CHARITY IN 2017

---

Presented at Society for Low Temperature Biology Science meeting.  
British Antarctic Survey, Aurora Centre, Cambridge.  
19 - 20<sup>th</sup> September 2017.

#### **Cryopreservation and Recovery of a Clinical Scale Bio-Artificial Liver (BAL) Based On Alginate Cell Spheroids.**

Erro E, Mendonca-Silva J, Bragg K, Puschmann E, Bundy J, Chalmers S, Modi S, Butler S, Planer G, Fuller B, Hodgson H, Selden C.

Presented at Society for Low Temperature Biology Science meeting.  
British Antarctic Survey, Aurora Centre, Cambridge.  
19 - 20<sup>th</sup> September 2017.

#### **Developing a small scale fluidised bed bioreactor for 3-D cell culture and in vitro testing.**

Mendonca-Silva J, Erro E, Mukhopadhyay T, Fuller B, Selden C.

Presented at Future Investigators of Regenerative Medicine.  
Hotel Cap Roig, Girona, Spain.  
25 – 28<sup>th</sup> September 2017.